Anne M. Filppula

M. Niemi, J. Backman, M. Neuvonen, 2021, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Microsoft Word-4759486-file00

Anne M. Filppula, J. Laitila, A. Filppula, 2011 .

Clinical Studies on Drug–Drug Interactions Involving Metabolism and Transport: Methodology, Pitfalls, and Interpretation

M. Niemi, J. Backman, Anne M. Filppula, 2019, Clinical pharmacology and therapeutics.

Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions

P. Neuvonen, M. Niemi, J. Backman, 2018, Drug Metabolism and Disposition.

Validation and development of MTH1 inhibitors for treatment of cancer.

Y. Kallberg, P. Artursson, R. Zubarev, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Improved predictions of time-dependent drug-drug interactions by determination of cytosolic drug concentrations

P. Artursson, A. Mateus, Anne M. Filppula, 2019, Scientific Reports.

Autoinhibition of CYP3A4 Leads to Important Role of CYP2C8 in Imatinib Metabolism: Variability in CYP2C8 Activity May Alter Plasma Concentrations and Response

P. Neuvonen, J. Backman, M. Neuvonen, 2013, Drug Metabolism and Disposition.

Autoinhibition of CYP 3 A 4 Leads to Important Role of CYP 2 C 8 in Imatinib Metabolism : Variability in CYP 2 C 8 Activity May Alter Plasma Concentrations and Response s

P. Neuvonen, J. Backman, M. Neuvonen, 2012 .

Autoinhibition of CYP3A4 Leads to Major Role of CYP2C8 in Imatinib Metabolism: Variability in CYP2C8 Activity May Alter Plasma Concentrations and Response

P. Neuvonen, J. Backman, M. Neuvonen, 2012 .

Autoinhibition of CYP3A4 Leads to Major Role of CYP2C8 in Imatinib Metabolism: Variability in CYP2C8 Activity May Alter Plasma Concentrations and Response

P. Neuvonen, J. Backman, M. Neuvonen, 2012 .

Glucuronidation Converts Clopidogrel to a Strong Time‐Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drug–Drug Interactions

P. Neuvonen, M. Niemi, J. Backman, 2014, Clinical pharmacology and therapeutics.

In Vitro Assessment of Time-Dependent Inhibitory Effects on CYP2C8 and CYP3A Activity by Fourteen Protein Kinase Inhibitors

P. Neuvonen, J. Backman, Anne M. Filppula, 2014, Drug Metabolism and Disposition.

Translational aspects of cytochrome P450‐mediated drug–drug interactions: A case study with clopidogrel

J. Backman, Anne M. Filppula, A. Tornio, 2021, Basic & clinical pharmacology & toxicology.

Title Page In Vitro Assessment of Time-Dependent Inhibitory Effects on CYP 2 C 8 and CYP 3 A Activity by Fourteen Protein Kinase Inhibitors

P. Neuvonen, J. Backman, Anne M. Filppula, 2014 .

DMD057695 1202..1209

P. Neuvonen, J. Backman, Anne M. Filppula, 2014 .

Gemfibrozil Impairs Imatinib Absorption and Inhibits the CYP2C8‐Mediated Formation of Its Main Metabolite

P. Neuvonen, M. Niemi, J. Backman, 2013, Clinical pharmacology and therapy.

In Vitro Screening of Six Protein Kinase Inhibitors for Time‐Dependent Inhibition of CYP2C8 and CYP3A4: Possible Implications with regard to Drug–Drug Interactions

J. Backman, Anne M. Filppula, A. Filppula, 2018, Basic & clinical pharmacology & toxicology.

Potent mechanism‐based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates

P. Neuvonen, J. Backman, P. Neuvonen, 2012, British journal of pharmacology.

Gemfibrozil Markedly Increases the Plasma Concentrations of Montelukast: A Previously Unrecognized Role for CYP2C8 in the Metabolism of Montelukast

P. Neuvonen, M. Niemi, J. Backman, 2010, Clinical pharmacology and therapeutics.